Pitolisant in an Adolescent with Prader-Willi Syndrome.

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Prader-Willi syndrome (PWS) is a complex genetic disorder associated with various neurodevelopmental and behavioral challenges.
• Current treatment options for PWS symptoms, such as psychostimulants, may not be effective for all individuals.
• Pitolisant, a histamine H3 receptor antagonist/inverse agonist, enhances neurotransmission and alertness.

Purpose of the Study:

• To evaluate the potential therapeutic benefits of pitolisant in a pediatric patient with Prader-Willi syndrome (PWS).
• To assess the safety and tolerability of pitolisant in this patient population.
• To explore pitolisant's efficacy in managing complex symptoms including obsessive-compulsive disorder (OCD) and autism spectrum disorder (ASD) in the context of PWS.

Main Methods:

• Case report detailing the administration of pitolisant to a 15-year-old female diagnosed with PWS, OCD, ASD, and mild intellectual disability.
• Clinical observation and assessment of symptom changes and adverse events following pitolisant initiation.
• Review of pitolisant's mechanism of action, focusing on H3 receptor modulation and its downstream effects on neurotransmitter systems.

Main Results:

• Pitolisant administration was associated with potential improvements in certain symptoms.
• The medication was generally well-tolerated, with minimal observed side effects.
• The case highlights pitolisant's potential role in managing complex behavioral and neurological symptoms in PWS.

Conclusions:

• Pitolisant demonstrates potential as a therapeutic option for individuals with Prader-Willi syndrome (PWS) exhibiting challenging symptoms.
• Consideration of pitolisant is warranted for PWS patients who do not respond adequately to psychostimulant therapy.
• Further research into pitolisant's efficacy and safety in PWS is recommended.